Form D · Pharmaceuticals
TENAX THERAPEUTICS, INC.
Chapel Hill, NC · CIK 0000034956
Offering snapshot reported Aug 23, 2024 · SEC filing
- Reported sold
- $99.7M Offering amount: $175M
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 8, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 23, 2024 | Initial | $99,681,169 | No comparison | 24 | SEC filing |
| Jun 1, 2022 | Initial | $8,000,000 | No comparison | 1 | SEC filing |
| Jul 20, 2021 | Initial | $9,999,998 | No comparison | Not reported | SEC filing |
| Jul 22, 2020 | Initial | $5,173,587 | No comparison | 1 | SEC filing |
| Mar 27, 2020 | Initial | $317,167 | No comparison | 1 | SEC filing |
| Nov 29, 2013 | Initial | $6,579,122 | No comparison | 4 | SEC filing |
| Sep 3, 2013 | Initial | $4,600,000 | No comparison | 1 | SEC filing |
| Aug 7, 2013 | Initial | $52,900 | No comparison | 1 | SEC filing |
| Mar 8, 2013 | Initial | $2,100,000 | No comparison | 2 | SEC filing |
| Jun 22, 2009 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jun 10, 2009 | Initial | $5,250,000 | No comparison | 2 | SEC filing |
| Jan 29, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Aug 8, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $6.83M
- Finders' fees
- $0
- Form D file number
- 021-522335
The Total Remaining to be Sold represents pre-funded warrants and warrants issued at closing that have not been exercised.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners LLC | 39011 | |
| Guggenheim Securities, LLC | 40638 | |
| William Blair & Company, L.L.C. | 1252 | |
| Roth Capital Partners, LLC | 15407 |
Source: Form D, filed Aug 23, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| June Almenoff | Director |
| Ronald R. Blanck | Director |
| Steven Boyd | Director |
| William A Chatfield | Director |
| Michael Davidson | Director |
| Anthony Di Tonno | Director, Executive |
| Declan Doogan | Director |
| Melville Engle | Director |
| Christopher T. Giordano | Director, Executive |
| Lawrence R. Hoffman | Executive |
| Robyn M. Hunter | Director |
| Michael Jebsen | Executive |
| John Kelley | Executive |
| Richard Kiral | Director, Executive |
| Gerald Klein | Director |
| Eliot Lurier | Executive |
| Keith Maher | Director |
| James Mitchum | Director |
| Gregory Pepin | Director |
| Gerald T. Proehl | Director |
| Chris A. Rallis | Director |
| Stuart Rich | Director, Executive |
| Charles Seeman | Executive |
| Bruce Spiess | Director |
| Chris Stern | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
101 Glen Lennox Drive Suite 300
Chapel Hill, NC, 27517
Chapel Hill, NC, 27517